- HUTCHMED (HCM, Financial) to present new and updated data at AACR Annual Meeting 2025 in Chicago.
- Key studies focus on compounds savolitinib, fruquintinib, and surufatinib.
- Highlighted research includes the SAVANNAH study, multiple fruquintinib studies, and surufatinib investigations.
HUTCHMED (HCM), a leading biopharmaceutical company, will present a series of new and updated data from its clinical studies at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place in Chicago from April 25-30, 2025. The presentations will focus on several compounds discovered by HUTCHMED, including savolitinib, fruquintinib, and surufatinib, which target various cancer treatments.
The presentations comprise both sponsored and investigator-initiated studies, addressing multiple facets of cancer therapy. Among the notable highlights is the SAVANNAH study, which examines plasma clearance in non-small cell lung cancer (NSCLC) patients treated with a combination of savolitinib and osimertinib.
Moreover, several studies involving fruquintinib will be showcased, primarily focusing on colorectal cancer treatment. These include research on sequential therapy, maintenance therapy, and combination treatments, underscoring fruquintinib's potential as a significant player in colorectal cancer management.
In addition, the meeting will feature multiple investigations into surufatinib's efficacy in different cancer types. This includes its use in combination therapies with sintilimab and capecitabine for bowel cancer, as well as PD-1 antibody and chemotherapy for pancreatic cancer. These studies highlight HUTCHMED's commitment to developing innovative cancer treatment strategies.
This comprehensive presentation at the AACR underscores HUTCHMED's dedication to advancing cancer therapies and improving patient outcomes worldwide. The data from these studies are instrumental in continuing the development of targeted cancer therapies and may offer new hope for patients battling various forms of cancer.
